Quick Facts

• Support for Allergic Rhinitis: May be used to help manage the common physical symptoms associated with seasonal allergies.
• Symptom Relief: Addresses aspects like sneezing, a runny nose, and itching of the nose, throat, and eyes.
• Nasal Congestion: Intended to help relieve a stuffy nose that can occur due to upper respiratory congestion.

---

What Rinolast D Treats: Main Uses and Benefits

Rinolast D is a combination product utilized in the temporary management of symptoms associated with seasonal allergic rhinitis, commonly known as hay fever. The medication may assist in mitigating several familiar physical expressions of an allergic response.

Its primary therapeutic domain involves providing relief from the discomforts of upper respiratory congestion. This includes addressing the occurrence of sneezing, which is a frequent symptom of allergies. It also is intended to help manage a runny nose, otherwise known as rhinorrhea. Furthermore, Rinolast D may be used to help alleviate the sensation of itching in the nose, on the roof of the mouth, or in the throat, as well as the irritation of watery eyes often linked to seasonal allergies.

By including a decongestant component, the product is intended to help reduce nasal congestion, assisting with a stuffy nose to support easier breathing. The overall purpose of using this medication is to help improve daily comfort during allergy season by managing these physical symptoms.

Who Can and Cannot Use Rinolast D?

Rinolast D is a fixed-dose combination medicine containing Fexofenadine and Phenylephrine HCl. Eligibility for use is determined by age, pre-existing health conditions, and physiological status, as defined in regulatory labeling.

Eligibility Criteria Summary

Classification	Eligibility Status (Official Regulatory Statement)
Approved Population	Adults and adolescents ge 12 years of age.
Pediatric Restriction	Not recommended for children under mathbf12 mathbfyears mathbfof mathbfage (use not established).
Pregnancy/Lactation	Not recommended; use only if potential benefit outweighs risk during pregnancy.

---

Absolute Contraindications (Must NOT Use)

The medicine is mathbfcontraindicated in patients with specific high-risk conditions, primarily due to the Phenylephrine component:

• Severe Hypertension or Severe Coronary Artery Disease (CAD).
• Use of a Monoamine Oxidase Inhibitor (MAOI) within the last mathbf14 mathbfdays.
• Known hypersensitivity to Fexofenadine, Phenylephrine, or any component.
• Narrow-Angle Glaucoma, Hyperthyroidism, or conditions leading to Urinary Retention.

Conditional use and mathbfcaution are also required for severe renal impairment and in the elderly (mathbfge 65 mathbfyears).

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Rinolast D, a combination product containing Fexofenadine and Phenylephrine Hydrochloride, strictly based on government regulatory labeling.

---

Official Regulatory Interaction Classifications

Classification Type	Interacting Agent	Regulatory Description
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to the risk of severe hypertensive crisis (Phenylephrine component). This prohibition extends for two weeks after stopping MAOI therapy.
Exposure Increase	Oral Ketoconazole, Oral Erythromycin	Significantly increases the plasma concentration (AUC and Cmax) of Fexofenadine, related to changes in P-glycoprotein transport.
Exposure Decrease	Aluminum/Magnesium Antacids	Administration decreases the systemic exposure of Fexofenadine. Timing separation is required to mitigate this effect.
Pharmacodynamic	Oxytocic Drugs, Sympathomimetic Agents	Risk of additive effects, particularly potentiation of the Phenylephrine pressor effect.

---

Administration Requirements and Restrictions

To minimize reduced absorption, the administration of Rinolast D must be separated from antacids containing aluminum and magnesium by at least 15 minutes to 2 hours. Consumption of fruit juices, specifically grapefruit, orange, or apple, may officially reduce the bioavailability of the Fexofenadine component. Caution regarding increased drug effects is noted for patients with renal dysfunction due to slower clearance of the medicine from the body.

How Rinolast D Works: Mechanism of Action

---

Blocking Histamine Signaling at the H1 Receptor

This mechanism centers on the antagonism of Histamine H1 receptors, which are key molecular targets for the receptor antagonist component. This action suppresses histamine's effect on target cells, thereby modifying early molecular steps that result in reduced capillary permeability and decreased sensory nerve stimulation.

---

Activating alpha1 Receptors for Nasal Vasoconstriction

The decongestant mechanism engages the Alpha-1 (alpha1) Adrenergic receptor pathway by acting as an agonist. This initiates signaling sequences that cause the smooth muscles in the nasal lining's blood vessels to contract, which decreases local tissue volume.

---

Modulating Dual Pathways for Combined Action

The drug's overall mechanism-of-action involves the simultaneous engagement of these two distinct mechanistic domains: blocking inflammation-related signaling and activating sympathetic vascular tone. This results in a modulated state within targeted peripheral pathways, contributing to a reduction in both microvascular plasma extravasation and local tissue volume.

How to Use Rinolast D — Administration Instructions

This section summarizes the directions for the use of Rinolast D.

Administration Details

Rinolast D is supplied as a tablet (coated tablet, in some formulations) intended for oral use, meaning it must be swallowed by mouth. The instructions define the required dosage and frequency to maintain consistent use.

Usage Component	Instruction
Route of Administration	Oral (Swallowed by mouth)
Dosing Schedule	One tablet
Frequency	Twice a day (Every 12 hours)
Timing with Food	With or without food
Preparation	Swallow the tablet whole. Do not crush, chew, or break the tablet.

Rules for Missed Doses

Following the prescribed schedule is essential for proper administration. If a dose is missed, the following guidance is provided:

1. Take the missed dose as soon as you remember it.
2. Skip the missed dose if it is almost time for your next regularly scheduled dose.
3. Do not take two doses at the same time to make up for a missed dose.

These instructions establish a procedure for taking the medicine, focusing on a twice-daily routine (every 12 hours) that can be taken independently of meals. This adherence to timing and method is the fundamental procedural requirement for using Rinolast D as directed.

Research Evidence / Overview of Studies for Rinolast D

Evidence for Use in Seasonal Allergic Rhinitis

Research exploring Rinolast D has focused on seasonal allergic rhinitis, a condition characterized by fluctuating and episodic manifestations. The evidence base primarily relies on short-term, randomized controlled trials (RCTs) where researchers monitored patient-reported outcomes describing perceived discomfort. The research team conducting these trials set out to record changes in common allergy symptoms, such as sneezing, runny nose, and nasal itching. Studies monitored changes in Total Symptom Score (TSS) over defined short time intervals in populations that received Rinolast D. High-level safety findings from these trials were also reported.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Research examined Rinolast D in studies focusing on Chronic Idiopathic Urticaria (CIU), a condition involving periods of heightened symptoms. The evidence base comes largely from placebo-controlled trials. Research explored outcomes linked to inflammatory or irritative states, specifically focusing on patient-reported outcomes describing perceived discomfort from itching (pruritus) and the number of visible skin welts or hives. Studies monitored outcomes reflecting daily functioning or activity level. Findings indicate data show patterns related to the study participants' symptom intensity or variability.

Long-Term Studies and Durability of Reported Outcomes

Research describing long-term outcomes for Rinolast D is generally limited. While some studies monitored participant outcomes over defined time intervals that extended beyond a few weeks, the duration of most primary registration trials was short. This means that long-term outcomes are not fully established, and evidence is limited regarding the long-term status of symptoms over many months or years.

What Is Still Uncertain About Rinolast D Research

The existing research contributes to the broader evidence landscape but also highlights areas where research is still needed. Evidence limitations include the fact that follow-up durations were often limited. Data for certain groups, such as the elderly or patients with specific underlying conditions, remain insufficient. Furthermore, comparative evidence that directly contrasts Rinolast D against all other similar available treatments is lacking in some contexts. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the studies.

Key Studies & References

1. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials

Common questions about Rinolast D (FAQ)

---

Q: Can I take this medication if I have high blood pressure?

A: Official regulatory labeling indicates that Rinolast D is contraindicated (must not be used) in patients who have severe hypertension (very high blood pressure) or severe coronary artery disease. The decision to use this medicine for non-severe or controlled high blood pressure should be reviewed by a healthcare professional, as the decongestant component has the potential to raise blood pressure.

Q: What is Rinolast D used for?

A: According to the official product information, Rinolast D is indicated for the relief of symptoms associated with seasonal allergic rhinitis, commonly known as hay fever. This includes relieving both nasal symptoms like congestion, and non-nasal symptoms like sneezing and itching.

Q: How is the medication physically eliminated or broken down by the body?

A: The Fexofenadine component is minimally broken down by the liver. It is primarily eliminated from the body unchanged in the feces (bile) and urine. Because clearance of the medicine involves the kidneys, regulatory information notes that caution is required in patients who have impaired kidney function.

Q: How long does it take for Rinolast D to start working after I take a dose?

A: Studies and official information indicate that the antihistamine component, Fexofenadine, is rapidly absorbed after the tablet is taken. Maximum concentrations of the drug in the blood are generally reached within one to three hours, which corresponds to when effects may begin to be noticed.

Q: Can Rinolast D be split in half, or should it be swallowed whole?

A: The official administration instructions for Rinolast D advise that the tablet must be swallowed whole. The instructions require the tablet not to be crushed, chewed, or broken, which is necessary to ensure the medicine works as intended.

Q: What is the expiration date on the Rinolast D box, and how do I know when to throw it out?

A: The expiration date is printed on the product’s original packaging or label. The medicine should not be used past the expiration date. For guidance on the proper disposal of expired or unused medicine, information can be obtained from a pharmacist.

Storage and Disposal Requirements for Rinolast D

Rinolast D must be stored at Controlled Room Temperature, which is defined by regulatory bodies as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and moisture and should be kept from freezing to maintain stability.

Packaging and Child Safety

To ensure quality, the medicine must be kept in its original container and the cap must be tightly closed. A mandatory safety requirement is to keep the medication out of the sight and reach of children and to lock safety caps securely.

Disposal Instructions

Official disposal guidelines require that unused or expired Rinolast D not be thrown away via wastewater or household waste to protect the environment. Consult a pharmacist for instructions on proper pharmaceutical waste disposal or local drug take-back programs.